10x Genomics, Inc. (NASDAQ:TXG - Get Free Report)'s share price rose 7% during mid-day trading on Wednesday . The company traded as high as $7.70 and last traded at $7.64. Approximately 580,407 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 2,122,295 shares. The stock had previously closed at $7.14.
Wall Street Analyst Weigh In
TXG has been the topic of several research analyst reports. Weiss Ratings reiterated a "sell (e+)" rating on shares of 10x Genomics in a report on Tuesday, April 8th. Barclays reduced their price target on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating on the stock in a research report on Thursday. UBS Group dropped their price objective on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. Stifel Nicolaus reduced their target price on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Finally, Canaccord Genuity Group dropped their price target on shares of 10x Genomics from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $19.79.
Get Our Latest Stock Analysis on TXG
10x Genomics Trading Up 3.2 %
The firm has a market cap of $1.01 billion, a PE ratio of -5.44 and a beta of 2.01. The business has a fifty day moving average price of $10.44 and a 200 day moving average price of $13.90.
10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. On average, research analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.
Insider Transactions at 10x Genomics
In related news, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the transaction, the insider now owns 335,324 shares of the company's stock, valued at $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Serge Saxonov sold 5,092 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $56,368.44. Following the sale, the chief executive officer now directly owns 879,482 shares of the company's stock, valued at approximately $9,735,865.74. This represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.03% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Signaturefd LLC lifted its holdings in shares of 10x Genomics by 424.6% during the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company's stock worth $26,000 after purchasing an additional 1,452 shares during the period. GF Fund Management CO. LTD. purchased a new position in 10x Genomics during the 4th quarter worth $32,000. Blue Trust Inc. lifted its stake in shares of 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after acquiring an additional 1,299 shares during the period. Sound Income Strategies LLC lifted its stake in shares of 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after acquiring an additional 1,330 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of 10x Genomics in the fourth quarter valued at about $52,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.
10x Genomics Company Profile
(
Get Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Articles
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
